BioCentury | Dec 14, 2018
Company News

Shionogi invests in Vast, gains first rights to negotiate license for antimicrobial

...Ltd. (Tokyo:4507) and separately granted the Japanese company first right of negotiation to in-license Vast's BIOC51...
...that it received a grant from the Cystic Fibrosis Foundation to support development of BIOC51. BIOC51...
...fibrosis. Vast Therapeutics Inc., Durham, N.C. Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Business: Infectious Shannon Lehnbeuter BIOC51 Shionogi...
Items per page:
1 - 1 of 1